For this, we first confirmed that various pharmacological inhibitors of inflammasomes, including Ac-YVAD-cmk and MCC950, selective inhibitors of caspase-1 and NLRP3, respectively, and interleukin-1 receptor antagonist (IL-1Ra) significantly decreased the cell viability of MCF-7 (Figure 5A) and T47D breast cancer cells (Figure S2A) but not triple-negative MDA-MB-231 breast cancer cells (Figure S2B), suggesting that inflammasomes activation drives growth of estrogen receptor (ER)-positive breast cancer cells in our experimental conditions. The gene discussed is ESR1; the disease is breast cancer.